Beacon Capital Management LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Beacon Capital Management LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 41.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 142 shares of the medical research company’s stock after selling 100 shares during the quarter. Beacon Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $72,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Castle Rock Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 9.8% during the 4th quarter. Castle Rock Wealth Management LLC now owns 1,801 shares of the medical research company’s stock worth $956,000 after acquiring an additional 161 shares in the last quarter. Covea Finance raised its position in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Covea Finance now owns 69,111 shares of the medical research company’s stock worth $36,683,000 after acquiring an additional 4,500 shares in the last quarter. Somerset Trust Co acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $219,000. First Affirmative Financial Network raised its position in shares of Thermo Fisher Scientific by 9.8% during the 4th quarter. First Affirmative Financial Network now owns 1,774 shares of the medical research company’s stock worth $942,000 after acquiring an additional 158 shares in the last quarter. Finally, Bartlett & CO. Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 2.1% during the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 173,885 shares of the medical research company’s stock worth $92,731,000 after acquiring an additional 3,541 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.1 %

Shares of TMO stock opened at $584.15 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a market capitalization of $222.74 billion, a P/E ratio of 37.81, a price-to-earnings-growth ratio of 2.49 and a beta of 0.80. The business’s 50 day moving average is $559.33 and its two-hundred day moving average is $518.31.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the previous year, the business earned $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be issued a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the sale, the chief executive officer now owns 43,608 shares in the company, valued at $24,011,436.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,277 shares of company stock valued at $28,513,384. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TMO. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 target price on the stock. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. HSBC initiated coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price target on the stock. Finally, Citigroup lifted their price target on Thermo Fisher Scientific from $530.00 to $575.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $596.00.

Get Our Latest Research Report on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.